Johnson & Johnson (JNJ.DE)
| Previous close | 134.82 |
| Open | 135.76 |
| Bid | 135.56 x 0 |
| Ask | 135.70 x 0 |
| Day's range | 135.42 - 136.26 |
| 52-week range | 132.78 - 161.20 |
| Volume | |
| Avg. volume | 3,528 |
| Market cap | 327.068B |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 21.71 |
| EPS (TTM) | 6.26 |
| Earnings date | 17 July 2024 |
| Forward dividend & yield | 4.55 (3.35%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | N/A |
PR NewswireLate-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study
Johnson & Johnson (NYSE: JNJ) announces patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo at 24 weeks compared to baseline (primary endpoint) in the Phase 2 DAHLIAS dose-ranging study of nipocalimab in adult patients living with Sjögren's disease (SjD). Response was demonstrated as early as Week 4 and continued to increase throughout the 24-week treatment period compared with patients recei
ZacksJohnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
PR NewswireTALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
Johnson & Johnson (NYSE: JNJ) announced today that long-term data from the Phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of median follow-up, triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) who were treated with TALVEY® (talquetamab-tgvs) maintained high overall response rates (ORR) and durable responses, irrespective of whether they had received prior T-cell redirection therapy.1 These data, featured in a poster presentation at the 2024 European
